☆ 4.1 Article

Design of paediatric trials with benefit-risk endpoints using a composite score of adverse events of interest (AEI) and win-statistics

JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2023)

Related references

Note: Only part of the references are listed.

Article Biology

On restricted mean time in favor of treatment

Lu Mao

Summary: The restricted mean time in favor (RMT-IF) is a nonparametric effect size used for complex life history data. It measures the average time the treated spend in a more favorable state than the untreated. This method can be easily estimated using plug-in Kaplan-Meier estimators.

BIOMETRICS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes

Gaohong Dong et al.

Summary: Conventional analyses of composite time-to-event outcomes using the time to the first event may not accurately reflect the most important outcome. Generalized pairwise comparisons and win statistics have been proposed as alternatives, but they have typically been used separately. This article examines the use of these three win statistics jointly for time-to-event outcomes and shows that they provide very similar p-values and statistical powers. The article also demonstrates that, when there is little censoring, the three win statistics can complement one another to show the strength of the treatment effect, but when there is significant censoring, adjustments may be needed. The R package WINS is recommended for calculations.

PHARMACEUTICAL STATISTICS (2023)

Add to Collection

Article Biology

Sample size formula for general win ratio analysis

Lu Mao et al.

Summary: The article introduces general formulas for sample size calculation in win ratio analysis using U-statistic theory to derive null variance and standard rank deviation for the test statistic. Simulation studies demonstrate accurate estimates for sample size across different settings. Real data from clinical studies are used to calculate sample sizes for future trials.

BIOMETRICS (2022)

Add to Collection

Letter Mathematical & Computational Biology

Sample size formula for a win ratio endpoint

Ron Xiaolong Yu et al.

STATISTICS IN MEDICINE (2022)

Add to Collection

Article Mathematical & Computational Biology

Calculating power for the Finkelstein and Schoenfeld test statistic for a composite endpoint with two components

Thomas J. Zhou et al.

Summary: The Finkelstein and Schoenfeld (FS) test is a popular method for analyzing prioritized composite endpoints. We propose an analytical solution for calculating power and sample size for two-component hierarchical composite endpoints, which is computationally efficient and practical compared to the standard simulation approach.

STATISTICS IN MEDICINE (2022)

Add to Collection

Article Pharmacology & Pharmacy

Adjusting win statistics for dependent censoring

Gaohong Dong et al.

Summary: For composite outcomes that can be prioritized by clinical importance, win ratio, net benefit, and win odds are used to compare patients pairwise and generate win proportions. These win statistics have gained attention in methodological research and clinical trial design. Censoring in time-to-event outcomes can introduce bias, but inverse-probability-of-censoring weighting can correct this bias, and the CovIPCW-adjusted win statistics are shown to be unbiased estimators of treatment effect in the presence of dependent censoring.

PHARMACEUTICAL STATISTICS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials

Samvel B. Gasparyan et al.

Summary: The win odds method is a distribution-free approach for comparing distributions of two independent random variables, particularly useful in analyzing ordinal scale endpoints in COVID-19 clinical trials. Power and sample size calculation formulas are provided for the win odds test for a single outcome, along with an implementation of the method in commonly used statistical software for full reproducibility.

JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2021)

Add to Collection

Article Dermatology

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial

Eric L. Simpson et al.

JAMA DERMATOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis

Xiaoxiang Zhou et al.

BMC MEDICINE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

The win ratio approach for composite endpoints: practical guidance based on previous experience

Bjorn Redfors et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

The win ratio approach for composite endpoints: practical guidance based on previous experience

Bjorn Redfors et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Mathematical & Computational Biology

The win ratio: On interpretation and handling of ties

Gaohong Dong et al.

Statistics in Biopharmaceutical Research (2019)

Add to Collection

Article Mathematical & Computational Biology

Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints

J. Verbeeck et al.

STATISTICS IN MEDICINE (2019)

Add to Collection

Article Mathematical & Computational Biology

Estimands and Their Role in Clinical Trials

Mouna Akacha et al.

STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2017)

Add to Collection

Article Medicine, General & Internal

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

E. L. Simpson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Pharmacology & Pharmacy

Biometrical issues in the analysis of adverse events within the benefit assessment of drugs

Ralf Bender et al.

PHARMACEUTICAL STATISTICS (2016)

Add to Collection

Article Immunology

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)

Scott R. Evans et al.

CLINICAL INFECTIOUS DISEASES (2015)

Add to Collection

Article Medicine, General & Internal

The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma A Multicenter Retrospective Study from Northwest China

Yu Zheng et al.

MEDICINE (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

Stuart J. Pocock et al.

EUROPEAN HEART JOURNAL (2012)

Add to Collection

Article Mathematical & Computational Biology

Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

Marc Buyse

STATISTICS IN MEDICINE (2010)

Add to Collection

Article Pharmacology & Pharmacy

Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method

Yili Lu Pritchett et al.

PHARMACEUTICAL STATISTICS (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.